Sankyo Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our condensed consolidated financial statements and related notes... | May 9, 2023

/PRNewswire/ -- American Regent, Inc. is pleased to announce the launch of Selenious Acid Injection, USP in a new concentration and vial size. The Selenious...

(0) Large routine clinical practice study, ETNA-AF-Europe, demonstrates continued benefits of edoxaban across age groups and supports treatment in elderly patient populations, in line with those observed in ETNA-AF after one year and in ENGAGE AF-TIMI 48 ETNA-AF-Europe is part of the global ETNA-AF programme, which is the largest prospective, non-interventional study investigating a single non-vitamin K antagonist oral anticoagulant (NOAC) to date Data presented at the annual scientific meeting of the European Heart Rhythm Association Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) today a...

New two-years follow-up data from ETNA-AF-Europe reaffirms benefit of LIXIANA® (edoxaban) in people with atrial fibrillation 04/26/2021 | 03:01am EDT Send by mail : Message : Required fields Large routine clinical practice study, ETNA-AF-Europe, demonstrates continued benefits of edoxaban across age groups and supports treatment in elderly patient populations, in line with those observed in ETNA-AF after one year and in ENGAGE AF-TIMI 48 ETNA-AF-Europe is part of the global ETNA-AF programme, which is the largest prospective, non-interventional study investigating a single non-vitamin K anta...

Daiichi Sankyo UK, Limited: ENHERTU - (TRASTUZUMAB DERUXTECAN) NOW AVAILABLE VIA THE CANCER DRUGS FUND FOR THE TREATMENT OF HER2 POSITIVE METASTATIC BREAST CANCER Reimbursement decisions in Scotland, Wales, and Northern Ireland to be announced later this year Daiichi Sankyo UK, Limited (hereafter, Daiichi Sankyo) and AstraZeneca UK today welcome the news that the National Institute for Health and Care Excellence (NICE) has recommended Enhertu (trastuzumab deruxtecan) for use within the Cancer Drugs Fund (CDF) as an option for treating HER2 positive unresectable or metastatic breast cancer in...